关键字: 站内搜索:
多肽专栏

字号:   

诺华、辉瑞有意放弃,安进或成Onyx制药唯一竞购者

日期:2013年8月15日 09:27

  2013年8月14日讯 --彭博社8月13日报道,据知情人士爆料,诺华(Novartis)和辉瑞(Pfizer)将不会参与竞购Onyx制药,这使得安进(Amgen)成为唯一的竞购者。
 
  该知情人士称,诺华认为Onyx制药当前的估值太过昂贵,辉瑞最近也放弃了出价,阿斯利康(AstraZeneca)则仍在做尽职调查。若阿斯利康不投标,安进将没有竞争对手。
 
  8月6日,彭博社报道称,安进(Amgen)有意提高其收购要约报价,愿以每股130美元的出价收购Onyx制药。该知情人士透露,目前,安进的出价是最高的。
 
  7月22日,彭博社报道称,阿斯利康(AZN)、辉瑞(Pfizer)、诺华(Novartis)也在准备竞标Onyx制药,同时安进(Amgen)也仍然有兴趣收购Onyx制药。
 
  此前,Onyx制药曾拒绝了来自安进(Amgen)主动提出的100亿美元收购要约。安进提出的收购要约为每股全现金120美元,但Onyx制药董事会认为,安进的报价严重低估了该公司的价值和前景。
 
  据分析师预计,竞标的赢家将获得Onyx制药的血癌药物Kyprolis,截止2019年,该药的销售可能会飙升9倍至24亿美元。
 
  Onyx制药其他产品包括抗癌药物多吉美(Nexavar,用于肝癌和肾癌治疗)和Stivarga(用于胃癌治疗),该公司2012年收入3.62亿美元,80%销售来自这2个药物。
 
  英文原文:Novartis, Pfizer Said to Be Out of Bidding for OnyxBy Kristen Hallam & David Welch - 2013-08-13T20:05:25ZNovartis AG (NOVN) and Pfizer (PFE) Inc. won’t bid for Onyx Pharmaceuticals Inc. (ONXX), the maker of cancer drugs, leaving Amgen Inc. with only one possible rival bidder remaining, according to people familiar with the situation.
 
  Onyx’s current valuation makes it too expensive for Novartis, said one of the people, who asked not to be identified because the matter is private. Pfizer recently backed away from making a bid and is no longer doing due diligence, said one of the people. London-based AstraZeneca Plc is still doing due diligence, that person said.
 
  Novartis, AstraZeneca and New York-based Pfizer had expressed interest in South San Francisco, California-based Onyx, the maker of Kyprolis, a blood cancer drug approved last year for some patients. Amgen upped its initial $120-a-share bid to $130 a share last week, a person familiar with the matter said then. If AstraZeneca doesn’t bid, Amgen, the world’s biggest biotechnology company by sales, would have no competition.
 
  Novartis, based in Basel, Switzerland, still has people doing due diligence at Onyx, one of the people said. None of the other companies, including AstraZeneca, has made a bid to rival Thousand Oaks, California-based Amgen’s $130-a-share offer, the person said.
 
  Onyx is involved with several potential purchasers, Chief Executive Officer N. Anthony Coles said Aug. 9.
 
  Lori Melancon, a spokeswoman for Onyx, said the company wouldn’t comment on rumors and speculation. Novartis spokesman Eric Althoff, Pfizer spokeswoman Joan Campion and AstraZeneca spokeswoman Esra Erkal-Paler declined to comment.
 
  Onyx declined less than 1 percent to $124.88 at the close in New York, giving the company a market value of about $9.16 billion.

所属类别: 国际资讯

该资讯的关键词为:

  • 03

  • 04

  • 02

  • 01